Planet 13 (PLNH): The World's Biggest Dispensary, Taxed Into a Loss
🎙 Listen — Q&A podcast
RoboSystems Cannabis Coverage · Narrative Brief · Drafted June 29, 2026 Sources: SEC filings via RoboSystems MCP (CIK 0001813452) · Q1 2026 earnings call (May 13, 2026) · live market data (June 25–26, 2026)
1. The Hook
Planet 13 runs what it bills as the largest cannabis dispensary on earth — a 112,000-square-foot Las Vegas megastore with a coffee shop, a restaurant, an events stage, and a tourist-trap gravitational pull. And over the last four years, that business has never once turned a pretax profit. It has lost money every single year. Yet across those same four years it has handed the IRS roughly $44 million in income taxes — including $11.6 million in 2025 on a $52 million pretax loss, and $4.2 million last quarter in a three-month stretch where it lost money even before taxes.
That is not a typo and it is not bad management. It is Section 280E — the line of the tax code, written for drug traffickers, that forbids cannabis companies from deducting normal operating expenses and taxes them on gross profit instead of net income. The result is the purest, most absurd version of the cannabis tax trap in our entire coverage set: a company being taxed into its losses. The stock has noticed. At about 12.5 cents and a $42.5 million market cap, Planet 13 trades at a fresh 52-week low and is down ~32% over the past year — while the cannabis sector index it belongs to is up roughly 104%. The reason that gap can exist is the reason this coverage exists: almost nobody is doing the math on this name.
2. Company Snapshot
Planet 13 Holdings (CSE: PLTH; OTCQX: PLNH/PLNHF; CIK 0001813452) is a vertically integrated, Las Vegas–headquartered multi-state operator with about 650 employees. Its identity is retail and tourism: the flagship Planet 13 SuperStore and its sister destination DAZED!, both on the Vegas Strip corridor, plus the Medizin brand and house labels like TRENDI, Leaf and Vine, Dreamland, and HaHa. Beyond Nevada, it operates a Florida medical business (acquired via VidaCann, now ~40% of revenue) and dispensaries in Illinois. In February 2026 it finished exiting California entirely — selling its Orange County retail and distribution licenses and its Coalinga cultivation property — to concentrate on its three core states. This brief is built on the FY2025 Form 10-K (filed March 25, 2026) and the Q1 FY2026 10-Q and earnings call (May 13, 2026), with every figure verified against the SEC XBRL data through the RoboSystems graph.
3. The Financial Story
Start with the top line, because it frames everything else: revenue has gone nowhere for four years. It was $104.6M in 2022, $98.5M in 2023, $116.4M in 2024, and back down to $103.4M in 2025 — a 11% decline last year, and a trailing-twelve-month figure now around $96M. This is not a growth story being mispriced; it is a flat-to-shrinking retailer in a brutal market. Las Vegas tourism is still running about 7% below 2024 levels, Nevada wholesale prices are compressed, and — uniquely for Planet 13 — intoxicating-hemp shops up and down the Strip have been siphoning off cannabis demand with a product that faced none of the testing, tax, or age-gating rules a licensed dispensary does. Gross margin tells the same story of pressure: it slipped from 48.2% in 2024 to 38.6% in 2025, though management says the reported figure has since stabilized around the mid-40s (44.6% in Q1 2026) as the California drag rolls off.
Now the part that makes this company remarkable. Look at the gap between what it earns and what it pays in tax. In 2025 Planet 13 generated $39.9M of gross profit, lost $52.3M pretax after all its operating costs and impairments — and still recorded $11.6M of income tax expense, with cash-basis current tax of $13.7M. A normal company with a $52M pretax loss pays zero and banks a loss carryforward. Planet 13 pays eight figures. The filing says it plainly: 280E "essentially requires us to pay federal, and as applicable, state income taxes on gross profit, which presents a significant financial burden that increases our net loss." The tax-rate reconciliation puts the 2025 280E penalty at $18.6 million of nondeductible "controlled substances" expense — up from $12.3M in 2024. Over 2022–2025, the cumulative scoreboard is roughly $201M of pretax losses and ~$44M of income tax paid. No sector tells this story as starkly.
There is a second layer to the tax story that doubles as the biggest balance-sheet risk in the name. Like several MSOs, Planet 13 decided to fight 280E — it has "taken a position that its deduction of ordinary and necessary business expenses is not limited by Section 280E," and rather than pay the disputed amount, it has been accruing it as an uncertain tax liability. That reserve has ballooned from $0 at the end of 2023 to $19.3M (2024), $33.0M (2025), and $37.1M as of Q1 2026 — with a gross unrecognized tax benefit of $55.6M. Read that against the market: the disputed reserve ($37M) is now nearly the size of the entire equity market capitalization ($42.5M) — and the $55.6M gross amount Planet 13 says it shouldn't owe is larger than the whole company. The IRS has won roughly 40 of these challenges and recently moved to claw back a peer's refund (TerrAscend, $8.3M), so this is not a theoretical exposure. It is a real liability sitting on the books, accruing, and contested.
The saving grace — and it is a genuine one — is that the cash picture is less dire than the GAAP picture, and the debt load is small. The $63.9M net loss in 2025 was mostly non-cash: about $33M of impairments and write-downs (long-lived assets $17.6M, leases $6.4M, intangibles $5.9M, inventory $3.6M) plus depreciation. Operating cash flow was negative $14.2M for the year but, after the California exit and the "Wagon Trail" cultivation consolidation, ran roughly breakeven in Q1 2026. Crucially, Planet 13 carries only about $11M of actual interest-bearing debt — the ~$54M "debt" figure in data feeds is mostly $44M of operating lease liabilities on the SuperStore and dispensary real estate. There is no going-concern flag; management asserts adequate liquidity for the next twelve months. But the cushion is thin: $6.0M of unrestricted cash ($16.3M including restricted) against a recent burn rate, and a ~$9.75M credit line (5.65%) maturing around June 30, 2026 that needs to be rolled. This is a survival-and-stabilization story, not a growth story — and that distinction is the whole investment debate.
4. Catalyst Scenarios — How the Math Changes
The standard cannabis pro forma — "apply a normal tax rate to pretax income and watch earnings explode" — doesn't work here, because Planet 13 has no pretax income to re-rate. For this company the catalyst math is about cash and survival, which is actually a sharper lever.
280E relief — but mind the medical/adult-use split. The April 28, 2026 order moved state-licensed medical marijuana to Schedule III, which lifts 280E on medical income going forward. Planet 13's Florida business operates under a state medical license and is roughly 40% of revenue, so management says 280E "no longer applies to our Florida business on a go-forward basis." But its home base — Nevada — and Illinois are adult-use, still Schedule I, still fully exposed to 280E. So the partial, medical-only catalyst only reaches part of this company. The bigger prize is the broad rescheduling under the DEA hearing that begins June 29, 2026: if all marijuana moves to Schedule III, 280E falls away for Nevada and Illinois too. Here's why that matters more than any earnings multiple: Planet 13 has been paying $12–14M a year in cash taxes it would largely stop paying. Against a $42.5M market cap and a single-digit-million cash balance, eliminating ~$13M of annual cash outflow is roughly 30% of the company's market value, every year — and very likely the difference between bleeding and breakeven. The unresolved question Treasury hasn't answered is retroactivity and how the $37M disputed reserve gets treated; management expects more clarity on the Q2 call.
The hemp cleanup — a rare top-line catalyst. Most cannabis catalysts help the cost side. This one could help revenue, and it lands harder on Planet 13 than on almost anyone else because intoxicating hemp has been an unusually direct competitor in tourist-heavy Las Vegas. Clark County passed an ordinance in March 2026 tightening hemp-THC rules, effective mid-July 2026, and the federal intoxicating-hemp ban takes effect ~November 12, 2026. Management expects "operational benefits in the back half of the year as enforcement takes effect." If even a slice of that displaced demand migrates into the licensed SuperStore, it lands on a fixed-cost retail base where incremental sales are highly profitable.
Self-help is already in motion. Independent of Washington, Planet 13 has exited California (removing ~$2.5M/quarter of low-margin revenue and its associated overhead), consolidated Nevada cultivation, cut G&A by nearly $3M year-over-year, and just received OMMU approval (May 19, 2026) for a Florida BHO concentrate lab that should lift the mix in its largest market starting in Q2. Management frames Q2 2026 as "the first quarter that reflects the repositioned portfolio without the transition drag," with a stated path to positive adjusted EBITDA. The adjusted EBITDA loss has been small and shrinking ($2.4M in Q1 2025, $0.3M in Q4 2025, $2.3M in the transition-heavy Q1 2026).
Consolidation — target, not buyer. With a $42.5M market cap, ~$6M of unrestricted cash, and a contested tax reserve, Planet 13 has no capacity to acquire. But it owns a genuinely irreplaceable, brand-name tourist asset and a Florida medical footprint at a time when uplisting-minded operators are hunting medical-only structures. The honest read is that Planet 13 is far more plausible as an acquisition target — or a distressed consolidation candidate — than as a consolidator.
5. Valuation — What It's Worth If It's a Normal Business
A precise DCF on a cash-burning microcap would be false precision, so treat the following as scenario bands under explicitly stated assumptions, not a target.
What the market is pricing today. At ~12.5 cents, Planet 13 trades at roughly 0.4–0.5x revenue — the cheapest multiple in the entire cannabis comp set (Tier 3 average ~1.5x; billion-dollar MSOs 1–3x; consumer-staples peers 2–5x) — and at about 0.95x book value, though that book is soft after years of impairments. EV/EBITDA is not meaningful because EBITDA is negative. In plain terms, the market is pricing Planet 13 as a business that may not make it: zero analyst coverage beyond one boutique, OTC-only, a disputed 280E position ($37M booked, $55.6M gross) that rivals or exceeds its market cap, and a tight cash position.
Base case (280E persists, broad rescheduling stalls). Planet 13 keeps paying ~$13M/year in cash tax while grinding toward breakeven EBITDA on self-help. In that world the equity is a coin-flip on execution and the credit-line roll; a ~0.4–0.6x revenue multiple (implying roughly today's price to perhaps a modest premium, very roughly $0.10–$0.20) is defensible, and dilution risk caps the upside.
Rescheduling case (broad Schedule III removes 280E across the footprint). Cash tax goes toward zero, the ~$13M annual drain reverses, and a stabilized Planet 13 plausibly generates mid-single-digit-million free cash flow on ~$100M of revenue. Re-rating even to the low end of the Tier 3 cannabis band (~1.0–1.5x revenue) on a survival-confirmed business would imply an enterprise value several times today's ~$49M — a wide band, but the direction is unambiguous: removing 280E is worth more than the whole equity is worth today. The catch is that this case requires both the broad order and operational breakeven, and it does nothing on its own to erase the accrued back-tax reserve.
The framing to leave viewers with: this is implied value under stated assumptions, not advice and not a price target. Planet 13 is priced as a survival bet, and the catalysts that would change that are real but contingent.
6. Risks and Open Questions
The bear case is concrete. Liquidity is the clock: $6M of unrestricted cash, a recent cash burn, and a ~$9.75M credit line maturing around June 30, 2026 — a failure to roll it cleanly, or a slower-than-promised return to cash generation, points toward dilution at a 12-cent share price that would be deeply painful to holders. The 280E gambit can backfire: the $37M booked reserve nearly equals the market cap (and the $55.6M gross claim exceeds it), the IRS is winning these fights and clawing back peers' refunds, and an adverse outcome (with interest and possible penalties) would overwhelm the balance sheet. The catalysts may not fire: the broad rescheduling hearing that began June 29 is stacked with opponents, the medical-only order is under a pending D.C. Circuit stay, and a stay or reversal would remove even the Florida relief. The core market is weak: Las Vegas tourism is still below 2024, Nevada pricing is compressed, and the hemp-enforcement tailwind is a forecast, not yet a number in the stores ("we're not actually seeing that translate to numbers yet," per management). And it is a thinly traded OTC microcap with a co-CEO structure and an interim CFO — governance and liquidity discounts are warranted.
7. The Bottom Line
Planet 13 is the cleanest illustration in cannabis of why 280E is so destructive: a company that has never earned a pretax profit, taxed as if it had, paying ~$44M to the IRS over four years of losses and now carrying disputed 280E taxes that rival its own stock-market value. Today it is priced as a survival bet — the cheapest revenue multiple in the sector, near a 52-week low, ignored while the rest of cannabis rallied. What changes the math is not a clever earnings multiple but the removal of a cash drain: the medical-only rescheduling already helps its Florida 40%, and a broad Schedule III order would lift 280E off Nevada and Illinois too — worth more in annual cash than the entire company is worth today. Layer in a genuine hemp-enforcement tailwind in its home market and a self-help plan that has cut costs and exited California, and there is a credible path to breakeven. Whether the cash and the calendar cooperate before that path closes is the entire question. Watch three things: the Q2 results (the first "clean" quarter and management's promised 280E clarity), the credit-line refinancing, and the June 29 DEA hearing. Facts and framework here — you decide.
This analysis was built with RoboSystems, an open-source platform for direct, structured access to SEC filing data for every public company. Not investment advice. No price targets. No paid promotions. New customers get 50% off your first month with code CANNABIS50.